Tanruprubart
Based on 5 publication(s) in Google Scholar
Tanruprubart (ANX005) is a C1q inhibitor and C1q depleter. Tanruprubart is a human antibody expressed in CHO cells, with huIgG1 heavy chains and huκ light chains, and its predicted molecular weight (MW) is 145 kDa. For the isotype control of Tanruprubart, refer to Human IgG1 kappa, Isotype Control (HY-P99001). The IC50 of Tanruprubart is 346 ng/mL for humans and 259 ng/mL for rats; its EC50 is 3.8 ng/mL for humans, 5.2 ng/mL for rats, and 9.9 ng/mL for mice. Tanruprubart is applicable to the research of Guillain-Barré syndrome and Alzheimer's disease.
For research use only. We do not sell to patients.
- Purity: 99.047%
- CAS No.: 2065212-40-8
- Molecular Weight:145.78 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Tanruprubart
More
Biological Activity
Human lgG4 kappa
Human
C1q
Tanruprubart (ANX005) (Titered concentrations) binds with high, comparable affinity to serum-derived C1q from human, cynomolgus monkey, rhesus monkey, dog, and rat, has lower affinity for mouse C1q, and does not bind rabbit C1q[1].
Tanruprubart (Titered concentrations; 1 h) potently inhibits classical complement-mediated hemolysis in human, cynomolgus monkey, rhesus monkey, dog, and rat serum, with an average IC50 of ~350 ng/mL, and does not inhibit hemolysis in rabbit serum[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Tanruprubart (ANX005) (10-200 mg/kg; i.v.; single bolus dose; once weekly; 4 weeks) administered to cynomolgus monkeys (as single doses or weekly doses for 4 weeks) produces dose-dependent serum and CSF exposures, fully depletes free serum C1q and inhibits complement-mediated hemolysis at measurable reagent levels, fully occupies CSF C1q at higher doses, and shows no treatment-related toxicity at doses up to 200 mg/kg, resulting in a no observed adverse effect level (NOAEL) of 100 mg/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague Dawley rats (male and female, young adult, 8-9 weeks old)[1]
-
Dosage:10 mg/kg; 50 mg/kg; 100 mg/kg; 200 mg/kg
-
Administration:i.v.; once weekly; 4 weeks
-
Result:Depleted free C1q in rat serum at measurable reagent levels.\nShowed dose-proportional increases in serum Cmax; AUC increased greater than dose-proportionally between lower doses, and dose-proportionally between 100 and 200 mg/kg.\nIncreased mean CSF concentrations in a greater-than-dose-proportional manner, with CSF levels representing 0.1% to 0.2% of serum levels on days 38 and 50 of the GLP study.\nExhibited no treatment-related changes in clinical signs, body weight, food consumption, clinical pathology, gross pathology, organ weight, or histopathology at any dose tested.\nAchieved a no observed adverse effect level (NOAEL) of 200 mg/kg.
-
Animal Model:Cynomolgus monkeys (male and female, 2-4 years old)[1]
-
Dosage:15 mg/kg (single bolus); 100 mg/kg (single bolus); 10 mg/kg (weekly x4); 50 mg/kg (weekly x4); 100 mg/kg (weekly x4); 200 mg/kg (weekly x4)
-
Administration:i.v.; single bolus dose; once weekly; 4 weeks
-
Result:Depleted free C1q in monkey serum at measurable reagent levels, with free C1q returning to baseline only when reagent levels dropped below detection.\nInhibited ex vivo complement-mediated hemolysis completely at measurable reagent serum levels, with hemolysis activity returning to baseline when reagent levels declined.\nShowed dose-dependent increases in serum concentrations, with trough levels accumulating over weekly doses in the 50, 100, and 200 mg/kg groups (excluding animals with anti-drug antibody responses).\nIncreased mean CSF concentrations with dose, with CSF levels representing 0.04% to 0.11% of serum levels in the non-GLP study, and 0.02% to 0.13% of serum levels in the GLP study on day 29; these CSF levels fully occupied C1q in the CSF at 100 and 200 mg/kg doses on day 29.\nExhibited no treatment-related changes in clinical signs, body weight, food consumption, clinical pathology, gross pathology, organ weight, histopathology, ophthalmic findings, neurologic exams, vital signs, or electrocardiograms at any dose tested.\nAchieved a no observed adverse effect level (NOAEL) of 200 mg/kg.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG4-kappa
ELISA, FACS, Functional assay
-
Immobilized C1q Protein (HY-NP0194) can bind ANX005. The EC50 for this effect is 2.56 ng/mL.
Chemical Information
-
CAS No. 2065212-40-8
-
Appearance Liquid
-
Molecular Weight 145.78 kDa
-
Color Colorless to light yellow
-
Synonyms
ANX005
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (5)
-
Journal Impact Factor
-
Most Recent
-
Neuron
2025 Nov 18:S0896-6273(25)00803-7. PMID: 41260217 -
J Adv Res
Tocilizumab-loaded nanoparticles block IL-6R and reduce edema after intracerebral hemorrhage. [Abstract]2026 Feb 16:S2090-1232(26)00158-X. PMID: 41707962 -
Alzheimers Dement
Gut-derived bacterial vesicles carrying lipopolysaccharide promote microglia-mediated synaptic pruning. [Abstract]2025 Aug;21(8):e70331. PMID: 40731189 -
J Neuroinflammation
Intravitreal delivery of NMO-IgG causes primary retinal damage in the absence of optic nerve injury. [Abstract]2025 Mar 7;22(1):69. PMID: 40055743 -
Int Immunopharmacol
Piezo1 participates in sevoflurane-induced developmental neurotoxicity via neuroinflammation and synaptic damage in the hippocampus. [Abstract]2025 Jul 26:163:115284. PMID: 40716188
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tanruprubart Related Classifications
HY-P990545 Related Classifications
Powered by Bioz